BioSpace News Archive

- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a clinical-stage oncology company, today announced that final overall survival (OS) data from its randomized Phase 2 trial of trilaciclib in metastatic triple-negative breast cancer (mTNBC) were consistent with preliminary findings announced last year, and showed that trilaciclib significantly improved median OS for patients treated with trilaciclib in combination with a chemotherapy regimen

Samsung Bioepis Co., Ltd. and Biogen Inc. announced that the U.S. Food and Drug Administration has accepted for review the Biologics License Application for SB11, a proposed biosimilar referencing Lucentis®.

Kaken plans to launch ECCLOCK®for the treatment of primary axillary hyperhidrosis in Japan on November 26, 2020

Findings further support the differentiated multifactorial mechanism of action of VASCEPA and its robust clinical effectiveness in reducing major adverse cardiovascular events (MACE) in studied high-risk patients

PLX-R18 d emonstrated significant c linical improvements in Hb, ANC, and PLT among the high-dose cohort PLX-R1 8 was found to be safe and well-tolerated T opline results from the full Phase I clinical trial expected in Q1 2021 (n=21)

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter ended September 30, 2020 on Monday, November 23, 2020 , befor

Interim DSMB review at the midpoint of the first dose cohort affirmed no safety or tolerability concerns with 75 mg of CRV431 in NASH patients

Acquired from Gilead Sciences a portfolio of SYK inhibitors, including lead investigational therapy entospletinib being developed for frontline treatment of N PM1-mutated acute myeloid leukemia Expanded executive team and board of directors with hiring of COO and CFO and appointment of audit committee chair, respectively Completed upsized initial public offering of common stock on October 14, 2020, raising $28 7.5 million in gross proceeds

SummerBio streamlined and automated the entire process of high-quality RT-PCR testing to reduce cost and massively increase test volumes to meet the needs of the pandemic

KBP Biosciences, a clinical-stage biotechnology company dedicated to research, development, and commercialization of innovative medicines for the global market, today announced the appointment of Douglas W. Losordo, MD, FACC, FAHA to the newly created position of Chief Medical Officer, effective immediately